Skip to main content
SpringerLink
Log in
Book cover

Drugs Affecting Lipid Metabolism pp 283–292Cite as

Combined Drug Treatment of Severe Hypercholesterolemia

  • Chapter

  • 85 Accesses

Part of the book series: Medical Science Symposia Series ((MSSS,volume 2))

Abstract

Familial hypercholesterolemia and familial combined hyperlipidemia are the most threatening disorders of lipoprotein metabolism regarding premature atherosclerotic complications. Dietary and drug monotherapy often are not sufficient to control these disorders. Especially in patients with symptomatic coronary artery disease LDL-cholesterol should be lowered at least to 135 mg/dl (or even 100 mg/dl ?). This is often achieved only with combined treatment. As shown in figure 1 there are multiple options to combine lipid-regulating drugs with different sites of actions to interfere rather specifically according to the underlying defect of lipoprotein metabolism.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Packard, C.J., Stewart J.M., Morgan H.G., Lorimer A.R. and Shepherd J. (1980) ‘Combined drug therapy for familial hypercholesterolemia’, Artery 7:281–289

    PubMed  CAS  Google Scholar 

  2. Angelin B., Eriksson M. and Einarsson K. (1986) ‘Combined treatment with cholestyramine and nicotinic acid in heterozygous familial hypercholestrolemia: effects on biliary lipid composition’, Europ — Clin Invest 16:391–396

    Article  CAS  Google Scholar 

  3. Series, J.J., Gaw A., Kilday C, Bedford D.K., Lorimer A.R., Packard C.J. and Shepherd J. (1990) ‘Acipimox in combination with low dose cholestyramine for the treatment of type II hyperlipidaemia’, Br — din Pharmac 30:49–54

    Article  CAS  Google Scholar 

  4. Gylling H., Vanhanen H. and Miettinen T.A. (1989) ‘Effects of acipimox and cholestyramine on serum lipoproteins, non-cholesterol sterols and cholesterol absorption and elimination’, Eur — Clin Pharmacol 37:111–115

    Article  CAS  Google Scholar 

  5. Kane, J.P., Malloy M.J., Tun P., Phillips N.R., Freedman D.D., Williams M.L, Rowe J.S. and Havel R.J. (1981) ‘Normalization of low-density-lipoprotein levels in heterozygous familial hyperchoelsterolemia with — combined drug regimen’, New Engl — Med 304:251–258

    Article  CAS  Google Scholar 

  6. Illingworth, D.R., Rapp J.H., Phillipson B.E. and Connor W.E. (1981) ‘Colestipol plus nicotinic acid in treatment of heterozygous familial hypercholesterolemia’, Lancet 1:296–298

    Article  PubMed  CAS  Google Scholar 

  7. Kuo, P.T., Kostis J.B., Moreyra A.E. and Hayes J.A. (1981) ‘Familial type II hyperlipoproteinemia with coronary heart disease’, Chest 79:286–291

    Article  PubMed  CAS  Google Scholar 

  8. Blankenhorn, D.H., Nessim S.A., Johnson R.L, Sanmarco M.E., Azen S.P. and Cashin-Hemphill — (1987) ‘Beneficial effects of combined Colestipol-Niacin therapy on coronary atherosclerosis and coronary venous bypass grafts’, JAMA 257:3233–3240

    Article  PubMed  CAS  Google Scholar 

  9. Cashin-Hemphill, L, Mack W.J., Pogoda J.M., Sanmarco M.E., Azen S.P. and Blankenhorn D.H. (1990) ‘Beneficial effects of Colestipol-Niacin on coronary atherosclerosis’, JAMA 264:3013–3017

    Article  PubMed  CAS  Google Scholar 

  10. Pasquali R., Biso P., Parenti M. and Melchionda N. (1981) ‘Combined effects of probucol and cholestyramine in familial type II hyperlipoproteinaemia’, Lancet 1:1368

    Article  PubMed  CAS  Google Scholar 

  11. Kane, J.P., Malloy M.J., Ports T.A., Phillips N.R., Diehl J.C. and Havel R.J. (1990) ‘Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens’, JAMA 264:3007–3012

    Article  PubMed  CAS  Google Scholar 

  12. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C, Zhao X.Q., Bisson B.D., Fitzpatrick V.F. and Dodge H.T. (1990) ‘Regression of coronary artery disease as — result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B’, New Engl — Med 323:1289–1298

    Article  CAS  Google Scholar 

  13. Malloy, M.J., Kane J.P., Kunitake ST. and Tun P. (1987) ‘Complementarity of Colestipol, Niacin, and Lovastatin in treatment of severe familial hypercholesterolemia’, Ann Intern Med 107:616–623

    PubMed  CAS  Google Scholar 

  14. Goodman, D.S., Noble R.P. and Dell R.B. (1973) The effects of colestipol resin and of colestipol plus clofibrate on the turnover of plasma cholesterol in man’, — Clin Invest 52:2646–2655

    Article  PubMed  CAS  Google Scholar 

  15. Rose, H.G., Haft G.K. and Juliano J. (1976) ‘Clofibrate-induced low density lipoprotein elevation therapeutic implications and treatment by colestipol resin’, Atherosclerosis 23:413–427

    Article  PubMed  CAS  Google Scholar 

  16. Fellin R., Baggio G., Briani G., Baiocchi M.R., Manzato E., Baldo G. and Crepaldi G. (1978) ‘Long-term trial with colestipol plus clofibrate in familial hypercholesterolemia’, Atherosclerosis 29:241–249

    Article  PubMed  CAS  Google Scholar 

  17. Hunninghake, D.B., Bell C. and Olson — (1981) ‘Effects of Colestipol and Clofibrate, singly and in combination, on plasma lipid and lipoproteins in type lib hyperlipoproteinemia’, Metabolism 30:610–615

    Article  PubMed  CAS  Google Scholar 

  18. Hoogwerf, B.J., Peters J.R., Frantz I.D. and Hunninghake D.B. (1985) ‘Effect of clofibrate and colestipol singly and in combination on plasma lipids and lipoproteins in type III hyperlipoproteinemia’, Metabolism 34:978–981

    Article  PubMed  CAS  Google Scholar 

  19. Curtis, L.D., Dickson A.C., Ling K.L.E. and Betteridge J. (1988) ‘Combination treatment with cholestyramine and bezafibrate for heterozygous familial hypercholesterolemia’, Brit Med — 297:173–175

    Article  PubMed  CAS  Google Scholar 

  20. Series, J.J., Caslake M.J., Kilday C, Cruickshank A., Demant T, Lorimer A.R., Packard C.J. and Shepherd J. (1989) ‘Effect of combined therapy with bezafibrate and cholestyramine on low-density lipoprotein metabolism in type Ha hypercholesterolemia’, Metabolism 38:153–158

    Article  PubMed  CAS  Google Scholar 

  21. Fischer S., Hanefeld M., Lang P.D., Fucker K., Bergmann S., Gehrisch S., Leonhardt W. and JaroB W. (1990) ‘Efficacy of — combined bezafibrate retard-colestyramine treatment in patients with hypercholesterolemia’, Arzneim.-Forsch./Drug Res. 40:469–472

    CAS  Google Scholar 

  22. Jones, A.F., Hughes E.A. and Cramb R. (1988) ‘Gemfibrozil plus cholestyramine in familial hypercholesterolemia’, Lancet 1:776

    Article  PubMed  CAS  Google Scholar 

  23. East, C, Bilheimer D.W. and Grundy S.M. (1988) ‘Combination drug therapy for familial combined hyperlipidemia’, Ann Intern Med 109:25–32

    PubMed  CAS  Google Scholar 

  24. Dujovne, C.A., Krehbiel P., DeCoursey S., Jackson B., Chemoff S.B., Pittermann A. and Garty M. (1984) ‘Probucol with colestipol in the treatment of hyperchoelsterolemia’, Ann Intern Med 100:477–482

    PubMed  CAS  Google Scholar 

  25. Weisweiler, P. and Schwandt P. (1986) ‘Colestipol plus fenofibrate versus synvinolin in familial hypercholesterolemia’, Lancet 11:1212–1213

    Article  Google Scholar 

  26. Malmendier, C.L, Delcrolx C. and Lontie J.F. (1987) The effect of combined fenofibrate and cholestyramine therapy on low-density lipoprotein kinetics in familial hypercholesterolemia patients’, Clin Chim Acta 162:221–227

    Article  PubMed  CAS  Google Scholar 

  27. Dujovne, C.A., Chernoff S.B., Krehbiel P., Jackson B., DeCoursey S. and Taylor H. (1984) ‘Low-dose colestipol plus probucol for hypercholesterolemia’, Am — Cardiol 53:1514–1518

    Article  CAS  Google Scholar 

  28. Sommariva D., Bonfiglioli D., Tirrito M., Pogliaghi I., Branchi A. and Cabrini E. (1986) ‘Probucol and cholestyramine combination in the treatment of severe hypercholesterolemia’, Int — Clin Pharm Ther Toxicol 24:505–510

    CAS  Google Scholar 

  29. Kuo, P.T., Wilson A.C., Kostis J.B. and Moreyra A.E. (1986) ‘Effects of combined probucol-colestipol treatment for familial hypercholestrolemia and coronary artery disease’, Am — Cardiol 57:43H–48H

    Article  CAS  Google Scholar 

  30. Cashin-Hemphill, L, Spencer C.A., Nicoloff J.T., Blankenhorn D.H., Nessim S.A., Chin H.P. and Lee N.A. (1987) ‘Alterations in serum thyroid hormonal indices with colestipol-niacin therapy’, Ann Intern Med 107:324–329

    PubMed  CAS  Google Scholar 

  31. Mabuchi H., Sakao T., Sakai Y., Yoshimura A., Watanabe A., Wakasugi T., Koizumi J. and Takeda R. (1983) ‘Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia’, New Engl — Med 308:609–613

    Article  CAS  Google Scholar 

  32. Illingworth, D.R. (1984) ‘Mevinolin plus colestipol in therapy for severe heterozygous familial hypercholesterolemia’, Ann Intern Med 101:598–604

    PubMed  CAS  Google Scholar 

  33. Grundy, S.M., Vega G.L and Bilheimer D.W. (1985) ‘Influence of combined therapy with mevinolin and interruption of bile-acid reabsorption on low density lipoproteins in heterozygous familial hypercholesterolemia’, Ann Intern Med 103:339–343

    PubMed  CAS  Google Scholar 

  34. Vega, G.L. and Grundy S.M. (1987) Treatment of primary moderate hypercholesterolemia with lovastatin (Mevinolin) and colestipol)’, JAMA 257:33–38

    Article  PubMed  CAS  Google Scholar 

  35. Leren, T.P., Hjermann I., Berg K., Leren P., Foss O.P. and Viksmoen — (1988) ‘Effects of lovastatin alone and in combination with cholestyramine on serum lipids and apolipoproteins in heterozygotes for familial hypercholesterolemia’, Atherosclerosis 73:135–141

    Article  PubMed  CAS  Google Scholar 

  36. Witztum, J.L, Simmons D., Steinberg D., Beltz W.F., Weinreb R., Young S.G., Lester P., Kelly N. and Juliano J. (1989) ‘Intensive combination drug therapy of familial hyperchoelsterolemia with lovastatin, probucol, and colestipol hydrochloride’, Circulation 79:16–28

    Article  PubMed  CAS  Google Scholar 

  37. Jacob, B.G., Mohrle W., Richter W.O., Schwandt P. (1992) ‘Short-and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolemia’, Eur — Clin Pharmacol 42:353–358

    CAS  Google Scholar 

  38. Pan, H.Y., DeVault A.R., Swites B.J., Whigan D., Ivashkjv E., Willard D.A. and Brescia D. (1990) ‘Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia’, Clin Pharmacol Ther 48:201–207

    Article  PubMed  CAS  Google Scholar 

  39. Garg, A. and Grundy S.M. (1989) ‘Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM’, Diabetes 38:364–372

    Article  PubMed  CAS  Google Scholar 

  40. Ytre-Arne, K. and Nordoy A. (1989) ‘Simvastatin and cholestyramine in the long-term treatment of hypercholesterolemia’, — Int Med 226:285–290

    Article  CAS  Google Scholar 

  41. Illingworth, D.R. and Bacon S. (1989) ‘Influence of lovatatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia’, Circulation 79:590–596

    Article  PubMed  CAS  Google Scholar 

  42. Emmerich J., Aubert I., Bauduceau B., Dachet D., Chanu B., Erlich D., Gautier D., Jacotot B. and Rouffy J. (1990) ‘Efficacy and safety of simvastatin (alone or in association with cholestyramine). — 1-year study in 66 patients with type II hyperlipoproteinaemia’, Europ Heart — 11:149–155

    CAS  Google Scholar 

  43. Geisel J., Oette K. and Burrichter H. (1990) ‘HMG-CoA-Reduktase-lnhibitoren bei familiärer Hypercholesterinämie’, Fortschr Med 108:69–72

    Google Scholar 

  44. Molgaard J., Lundh B.L, von Schenck H. and Olsson A.G. (1991) ‘Long-term efficacy and safety of simvastatin alone and in combination therapy in treatment of hypercholesterolemia’, Atherosclerosis 91:S21–S28

    Article  PubMed  Google Scholar 

  45. Glueck, C.J., Speirs J. and Tracy T. (1990) ‘Safety and efficacy of combined gemfibrozil-lovastatin therapy for primary dyslipoproteinemias’, — Lab Clin Med 115:603–609

    PubMed  CAS  Google Scholar 

  46. Illingworth, D.R. and O’Malley J.P. (1990) The hypolipidemic effects of lovastatin and clofibrate alone and in combination in patients with type III hyperlipoproteinemia’, Metabolism 39:403–409

    Article  PubMed  CAS  Google Scholar 

  47. Lintott, C.J., Scott R.S., Nye E.R., Robertson M.L and Sutherland W.H.F. (1991) The hypolipidaemic effects of pravastatin (CS-514) alone and in combination with bezafibrate or acipimox in patients with primary hypercholesterolemia’, Diab Nutr Metab 4:117–122

    Google Scholar 

  48. Pierce, L.R., Wysowski D.K. and Gross T.P. (1990) ‘Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy’, JAMA 264:71–75

    Article  PubMed  CAS  Google Scholar 

  49. Illingworth, D.R. and Bacon S. (1989) Treatment of heterozygous familial hypercholestrolemia with lipid-lowering drugs’, Arteriosclerosis (Suppl I) 9:1-121-134

    Google Scholar 

Download references

Authors
  1. P. Schwandt
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Istituto di Scienze Farmacologiche, Università di Milano, Via Balzaretti 9, I-20133, Milano, Italy

    A. L. Catapano  & Rodolfo Paoletti (Direttore) &  (Direttore)

  2. Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA

    A. M. Gotto Jr. (Chairman) (Chairman)

  3. Department of Medicine, The Methodist Hospital, 6565 Fannin M.S. A601, Houston, TX, 77030-2797, USA

    Louis C. Smith (Professor of Experimental Medicine) (Professor of Experimental Medicine)

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Schwandt, P. (1993). Combined Drug Treatment of Severe Hypercholesterolemia. In: Catapano, A.L., Gotto, A.M., Smith, L.C., Paoletti, R. (eds) Drugs Affecting Lipid Metabolism. Medical Science Symposia Series, vol 2. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-1703-6_35

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-1703-6_35

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-4746-3

  • Online ISBN: 978-94-011-1703-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation